在缺乏基线数据时利用接种后数据估计HPV疫苗接种对HPV感染的保护效果
研究在瑞典南部和中部地区收集15-39岁女性型特异性HPV患病率数据,开发并验证仅利用接种后数据、以非疫苗型HPV为参考重建基线来估计HPV疫苗保护效果(PE)的方法。南部地区重建基线与实际基线高度一致(BC 82.7%),18-21岁女性对疫苗型HPV的PE为52.2%(95%CI 44.9-58.5),与实际基线估计的49.6%(43.2-55.5)接近;中部无基线地区PE为40.5%(31.6-48.5)。
要点
- 利用接种后数据和非疫苗型HPV参考可重建疫苗型HPV基线患病率。
- 南部地区重建基线与实际基线的一致性BC为82.7%。
- 18-21岁女性对疫苗型HPV的PE:重建基线52.2% vs 实际基线49.6%。
核心结论
- 仅利用接种后数据、通过非疫苗型HPV数据重建基线,可以估计HPV疫苗的保护效果。
研究设计与样本
- 研究收集瑞典南部地区疫苗接种前后15-39岁女性的型特异性HPV患病率数据,并在瑞典中部地区(无基线数据)仅收集接种后数据。
- 以年龄较大的未接种队列和瑞典南部地区作为参考,应用目标HPV型与非疫苗型HPV患病率之间的参考比值比,从接种后数据以Beta分布重建疫苗型HPV(HPV 6、11、16、18)的年龄特异性基线患病率。
- 通过计算重建基线与实际观察患病率之间的Bhattacharyya系数(BC)验证基线重建方法,并比较基于重建基线与实际基线的18-21岁女性PE估计值。
主要发现
- 在瑞典南部地区,针对疫苗型HPV的PE基于重建基线为52.2%(95%CI 44.9-58.5),基于实际基线为49.6%(95%CI 43.2-55.5)。
- 瑞典南部地区重建基线与实际基线之间的BC为82.7%。
- 在缺乏基线数据的瑞典中部地区,PE估计为40.5%(95%CI 31.6-48.5)。
关键数值与推荐
- 南部地区18-21岁女性对疫苗型HPV的PE:重建基线52.2%(95%CI 44.9-58.5) vs 实际基线49.6%(95%CI 43.2-55.5)。
- 中部地区18-21岁女性对疫苗型HPV的PE为40.5%(95%CI 31.6-48.5)。
- 重建基线与实际基线的一致性BC为82.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HPV vaccination programs have been introduced in large parts of the world, but monitoring of effectiveness is not routinely performed. Many countries introduced vaccination programs without establishing the baseline of HPV prevalences. We developed and validated methods to estimate protective effectiveness (PE) of vaccination from the post-vaccination data alone using references, which are invariant under HPV vaccination. METHODS: Type-specific HPV prevalence data for 15-39 year-old women were collected from the pre- and post-vaccination era in a region in southern Sweden. In a region in middle Sweden, where no baseline data had been collected, only post-vaccination data was collected. The age-specific baseline prevalence of vaccine HPV types (vtHPV, HPV 6, 11, 16, 18) were reconstructed as Beta distributions from post-vaccination data by applying the reference odds ratios between the target HPV type and non-vaccine-type HPV (nvtHPV) prevalences. Older non-vaccinated age cohorts and the southern Sweden region were used as the references. The methods for baseline reconstructions were validated by computing the Bhattacharyya coefficient (BC), a measure for divergence, between reconstructed and actual observed prevalences for vaccine HPV types in Southern Sweden, and in addition, for non-vaccine types in both regions. The PE estimates among 18-21 year-old women were validated by comparing the PE estimates that were based on the reconstructed baseline prevalences against the PE estimates based on the actual baseline prevalences. RESULTS: In Southern Sweden the PEs against vtHPV were 52.2% (95% CI: 44.9-58.5) using the reconstructed baseline and 49.6% (43.2-55.5) using the actual baseline, with high BC 82.7% between the reconstructed and actual baseline. In the middle Sweden region where baseline data was missing, the PE was estimated at 40.5% (31.6-48.5). CONCLUSIONS: Protective effectiveness of HPV vaccination can be estimated from post-vaccination data alone via reconstructing the baseline using non-vaccine HPV type data.
引用
- Vänskä S, Söderlund-Strand A, Uhnoo I, et al. Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. Vaccine. 2018. PMID: 29716776. doi:10.1016/j.vaccine.2018.04.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。